Medical Research Finder

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Glucagon like peptide 1 (GLP-1) receptor agonists & Type 2 diabetes (T2D)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Four Glucagon like peptide 1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes (1).

Glucagonlike peptide-1 (GLP-1) receptor agonists are well-established glucose-lowering medications for the treatment of type 2 diabetes and are associated with reductions in body weight, blood pressure reduction and a low risk of [hypoglycemia](brain://68StdqXsS0ONvVavgSm…

References (Sources)

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
Aroda et al. 2019 Diabetes Metab 45(5): 409-418
Review
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Jendle et al. 2016 Diabetes Metab Res Rev 32: 776-90
Review
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Nauck et al. 2016 Diabetologia 59: 266-7
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Aroda et al. 2017 Lancet Diabetes Endocrinol 5: 355-66
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Ahrén et al. 2017 Lancet Diabetes Endocrinol 5: 341-54
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Madsbad 2016 Diabetes Obes Metab 18(4): 317-32
Review
The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
Gu et al. 2016 Sci Rep 6: 32714
Meta-Analysis

AI Chat

5/28/2026

Chat with our artificial intelligence: